Quick Answer
Vir Biotechnology, Inc. reported Total Assets of $1.00 billion for the year ending 2025.
- Vir Biotechnology, Inc. showed a decrease of -28.3% in Total Assets from 2024 to 2025.
- This data is from Vir Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $422.64 million | Q1 2020: $477.11 million | Q2 2020: $672.24 million | Q3 2020: $943.26 million | Q1 2021: $1.14 billion | Q2 2021: $1.06 billion | Q3 2021: $1.21 billion | Q1 2022: $2.89 billion | Q2 2022: $2.62 billion | Q3 2022: $2.70 billion | Q1 2023: $2.67 billion | Q2 2023: $2.24 billion | Q3 2023: $2.04 billion | Q1 2024: $1.79 billion | Q2 2024: $1.67 billion | Q3 2024: $1.50 billion | Q1 2025: $1.31 billion | Q2 2025: $1.19 billion | Q3 2025: $1.02 billion.
- Over the full 8 years of available data (2018 to 2025), Vir Biotechnology, Inc.'s Total Assets has grown by 423.4%.
- Historical annual values: Fiscal year 2025: $1.00 billion | Fiscal year 2024: $1.40 billion | Fiscal year 2023: $1.92 billion | Fiscal year 2022: $2.80 billion | Fiscal year 2021: $1.95 billion | Fiscal year 2020: $918.76 million | Fiscal year 2019: $512.07 million | Fiscal year 2018: $191.60 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: